Editas Medicine - EDIT Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings or view top-rated stocks.

14 brokerages have issued 12-month target prices for Editas Medicine's shares. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they anticipate the company's share price to reach $15.33 in the next twelve months. This suggests a possible upside of 105.5% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.

Editas Medicine's stock was trading at $8.87 at the beginning of 2023. Since then, EDIT stock has decreased by 15.9% and is now trading at $7.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our EDIT earnings forecast.

Editas Medicine, Inc. (NASDAQ:EDIT) released its earnings results on Wednesday, February, 22nd. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.04. The firm had revenue of $6.54 million for the quarter, compared to the consensus estimate of $3.76 million. Editas Medicine had a negative trailing twelve-month return on equity of 50.28% and a negative net margin of 1,118.32%. Editas Medicine's quarterly revenue was down 47.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.61) earnings per share.

ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), AXS Green Alpha ETF (NXTE), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), SPDR S&P Biotech ETF (XBI), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (3.12%), Dimensional Fund Advisors LP (2.40%), Geode Capital Management LLC (2.01%), JPMorgan Chase & Co. (1.72%), Credit Suisse AG (1.43%) and Two Sigma Investments LP (1.39%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EDIT stock can currently be purchased for approximately $7.46.

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $514.52 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

The company employs 264 workers across the globe.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.